Effatpanah Hosein, Alamdary Ashkan, Hossein Tehrani Mohammad Javad, Mardani Rajab, Ahmadi Nayebali
Department of Public Health School of Asadabad, Hamedan University of Medical Sciences. Hamadan, Iran.
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Asian Pac J Cancer Prev. 2025 Jul 1;26(7):2407-2411. doi: 10.31557/APJCP.2025.26.7.2407.
Breast cancer is one of the most prevalent malignancies and a significant cause of cancer-related mortality among women. Identifying reliable biomarkers for early detection and monitoring is crucial for improving patient outcomes. Therefore, we evaluated circulating miR-6165 and miR-182-3p expression levels in breast cancer patients and explored their potential as biomarkers.
Plasma samples were collected from diagnosed breast cancer patients and healthy control subjects. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to assess the expression levels of miR-6165 and miR-182-3p. The data were analyzed using GraphPad Prism software (GraphPad Software, USA), and P-values at p < 0.05 were considered significant.
Our findings show that both miR-6165 and miR-182-3p are significantly up-regulated in breast cancer patients compared to healthy controls (p < 0.05). These findings were conducted with 50 patients and 50 healthy individuals and were not significant in the age group under 40 years but were substantial between 40 and 60 years (p < 0.05) and over 60 years (p < 0.01). This positive regulation highlights their potential role in diagnosis and monitoring of the disease. A sensitivity of 85% and specificity of 90% were observed for miR-6165, and a sensitivity of 80% and specificity of 88% for miR-182-3p. Furthermore, we provided an analysis of the targets of miR-6165 and miR-182-3p, along with the associated genes, to indicate the underlying mechanisms involved in breast cancer progression. These potential targets as therapeutic biomarkers, may provide overcome the challenges of tumor resistance, and a valuable impact on future research.
The elevated levels of circulating miR-6165 and miR-182-3p in breast cancer patients suggest their utility as promising non-invasive biomarkers for early detection and monitoring of breast cancer. Further validation studies are warranted to establish their clinical relevance and to explore their functional roles in breast cancer biology.
乳腺癌是最常见的恶性肿瘤之一，也是女性癌症相关死亡的重要原因。识别用于早期检测和监测的可靠生物标志物对于改善患者预后至关重要。因此，我们评估了乳腺癌患者循环中miR-6165和miR-182-3p的表达水平，并探讨了它们作为生物标志物的潜力。
收集确诊乳腺癌患者和健康对照者的血浆样本。采用定量实时聚合酶链反应（qRT-PCR）评估miR-6165和miR-182-3p的表达水平。使用GraphPad Prism软件（美国GraphPad软件公司）分析数据，p<0.05的P值被认为具有统计学意义。
我们的研究结果表明，与健康对照相比，miR-6165和miR-182-3p在乳腺癌患者中均显著上调（p<0.05）。这些研究共纳入50例患者和50名健康个体，在40岁以下年龄组中差异不显著，但在40至60岁（p<0.05）和60岁以上（p<0.01）年龄组中差异显著。这种正向调节突出了它们在疾病诊断和监测中的潜在作用。miR-6165的敏感性为85%，特异性为90%；miR-182-3p的敏感性为80%，特异性为88%。此外，我们对miR-6165和miR-182-3p的靶标以及相关基因进行了分析，以揭示参与乳腺癌进展的潜在机制。这些潜在靶标作为治疗性生物标志物，可能有助于克服肿瘤耐药性挑战，并对未来研究产生重要影响。
乳腺癌患者循环中miR-6165和miR-182-3p水平升高表明它们有望作为早期检测和监测乳腺癌的非侵入性生物标志物。有必要进行进一步的验证研究，以确定它们的临床相关性，并探索它们在乳腺癌生物学中的功能作用。
